Opioid receptor internalization contributes to dermorphin-mediated antinociception.
Microinjection of opioids into the ventrolateral periaqueductal gray (vlPAG) produces antinociception in part by binding to mu-opioid receptors (MOPrs). Although both high and low efficacy agonists produce antinociception, low efficacy agonists such as morphine produce limited MOPr internalization suggesting that MOPr internalization and signaling leading to antinociception are independent. This hypothesis was tested in awake, behaving rats using DERM-A594, a fluorescently labeled dermorphin analog, and internalization blockers. Microinjection of DERM-A594 into the vlPAG produced both antinociception and internalization of DERM-A594. Administration of the irreversible opioid receptor antagonist beta-chlornaltrexamine (beta-CNA) prior to DERM-A594 microinjection reduced both the antinociceptive effect and the number of DERM-A594 labeled cells demonstrating that both effects are opioid receptor-mediated. Pretreatment with the internalization blockers dynamin dominant-negative inhibitory peptide (dynamin-DN) and concanavalinA (ConA) attenuated both DERM-A594 internalization and antinociception. Microinjection of dynamin-DN and ConA also decreased the antinociceptive potency of the unlabeled opioid agonist dermorphin when microinjected into the vlPAG as demonstrated by rightward shifts in the dose-response curves. In contrast, administration of dynamin-DN had no effect on the antinociceptive effect of microinjecting the GABA(A) receptor antagonist bicuculline into the vlPAG. The finding that dermorphin-induced antinociception is attenuated by blocking receptor internalization indicates that key parts of opioid receptor-mediated signaling depend on internalization.
Macey
T A
TA
Department of Psychology, Washington State University Vancouver, 14204 NE Salmon Creek Avenue, Vancouver, WA 98686, USA.
Ingram
S L
SL
Bobeck
E N
EN
Hegarty
D M
DM
Aicher
S A
SA
Arttamangkul
S
S
Morgan
M M
MM
D000701:Analgesics, Opioid / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D034281:Dynamins / Q000037:antagonists & inhibitors; D005456:Fluorescent Dyes / Q000737:chemistry; D058787:GABA-A Receptor Antagonists; D008297:Male; D008845:Microinjections; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism; D018847:Opioid Peptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010147:Pain Measurement; D010455:Peptides / Q000494:pharmacology; D010487:Periaqueductal Gray / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000701:Analgesics, Opioid; D005456:Fluorescent Dyes; D058787:GABA-A Receptor Antagonists; D018847:Opioid Peptides; D010455:Peptides; D017450:Receptors, Opioid, mu; D003208:Concanavalin A; C030058:dermorphin; D009271:Naltrexone; C017120:chlornaltrexamine; D034281:Dynamins; D001640:Bicuculline
J Biol Chem. 2002 Sep 13;277(37):33783-90
12097326
J Neurosci. 1999 Jan 1;19(1):56-63
9870938
J Neurosci. 2002 Jul 1;22(13):5769-76
12097530
J Neurosci. 2006 Apr 12;26(15):4118-25
16611829
Mol Pharmacol. 1995 Apr;47(4):666-76
7723728
Brain Res. 1991 Sep 6;558(2):224-30
1664270
Brain Res. 1976 Feb 27;103(3):501-13
1252940
Mol Pharmacol. 2005 Oct;68(4):1127-32
16020743
Mol Pharmacol. 2005 Jan;67(1):280-7
15475572
J Neurosci Methods. 2008 May 30;170(2):285-93
18377995
J Pain. 2000 Sep;1(3 Suppl):57-65
14622844
J Biol Chem. 1996 Aug 9;271(32):19021-4
8702570
Mol Cell Neurosci. 2007 Jul;35(3):456-69
17513124
Brain Res. 1989 Oct 30;501(1):116-28
2572306
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17615-22
19822761
Br J Pharmacol. 2008 Mar;153 Suppl 1:S379-88
18059321
J Neurophysiol. 1992 Oct;68(4):1027-45
1432065
J Biol Chem. 2003 May 23;278(21):18776-84
12642578
Neuropharmacology. 2000 Jul 24;39(10):1707-19
10884553
Biochem J. 1989 Oct 15;263(2):533-8
2556997
Eur J Biochem. 1990 May 20;189(3):625-35
2161761
Curr Biol. 2008 Jan 22;18(2):129-35
18207746
Mol Pharmacol. 2008 Oct;74(4):972-9
18612077
Pain. 2009 Dec 15;147(1-3):210-6
19796879
Science. 1999 Dec 24;286(5449):2495-8
10617462
Mol Pharmacol. 2008 Apr;73(4):1301-8
18198283
Behav Brain Res. 2005 Oct 14;164(1):61-6
16029902
Traffic. 2007 May;8(5):462-70
17376169
Neuroscience. 2005;135(1):227-34
16084660
Neuron. 2001 Dec 6;32(5):829-39
11738029
J Neurosci. 2005 Mar 23;25(12):3192-8
15788776
Pain. 1995 Sep;62(3):287-293
8657428
J Pharmacol Exp Ther. 2009 Nov;331(2):412-8
19684256
Brain Res. 1994 Nov 28;665(1):85-93
7882023
Cell. 2002 Jan 25;108(2):271-82
11832216
Traffic. 2007 Jul;8(7):848-66
17587406
Curr Opin Neurobiol. 2003 Jun;13(3):348-53
12850220
Mol Pharmacol. 2000 Dec;58(6):1570-80
11093798
J Biol Chem. 2006 Nov 10;281(45):34515-24
16982618
J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
11504778
Brain Res. 2005 Jun 14;1047(1):65-71
15878767
PLoS One. 2009;4(5):e5425
19412545
Neuropharmacology. 2007 Oct;53(5):664-76
17845806
Brain Res. 2008 Mar 4;1197:85-93
18207137
J Neurosci. 2004 Sep 1;24(35):7699-706
15342737
Pharmacol Ther. 2008 Feb;117(2):199-206
18076994
Mol Pharmacol. 2008 Jan;73(1):178-90
17947509
J Biol Chem. 2003 Nov 14;278(46):45978-86
12939277
J Neurosci. 2003 Nov 19;23(33):10515-20
14627635
Naunyn Schmiedebergs Arch Pharmacol. 1982 Mar;318(4):368-9
7078669
Nat Rev Mol Cell Biol. 2009 Sep;10(9):609-22
19696798
Brain Res. 1988 Apr 26;447(1):25-34
2838129
Neural Plast. 2009;2009:516328
19266049
J Biol Chem. 1997 Dec 12;272(50):31648-56
9395506
Mol Endocrinol. 2004 Mar;18(3):640-52
14684845
Neuroscience. 2004;125(3):541-3
15099667
Br J Pharmacol. 2009 Sep;158(1):154-6
19719778
Pharmacol Biochem Behav. 2006 Sep;85(1):214-9
16979226
J Comp Neurol. 2003 Sep 15;464(2):197-207
12898612
Brain Res. 1998 Aug 31;804(1):159-66
9729359
Mol Pharmacol. 2004 Jul;66(1):106-12
15213301